Jaguar Health, Inc.

JAGX • Biotechnology

$0.60

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$487,091.444

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Positive free cash flow · 86.63Weak liquidity · 0.5Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 23, 2026, 12:11 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.60

Change0.00%

Shares Out809.12K

Market Cap$487.09K

Enterprise Value$9.46M

Beta-0.05

P/E-0.01

P/S0.02

P/B0.07

P/FCF-0.07

EV/Sales0.34

EV/EBITDA-0.24

Price$0.60

Change0.00%

Shares Out809.12K

Market Cap$487.09K

Enterprise Value$9.46M

Beta-0.05

P/E-0.01

P/S0.02

P/B0.07

P/FCF-0.07

EV/Sales0.34

EV/EBITDA-0.24

EV/FCF-1.40

Dividend Yield0.00%

Gross Margin67.21%

Oper. Margin-3.99%

Profit Margin-4.65%

Debt/Eq-2.52

Current Ratio0.50

Quick Ratio0.29

Target$3.21

Target Upside433.22%

Target Median$3.21

Target Range3.21 - 3.21

Volume74.62K

Avg Volume113.82K

EPS Surprise135.50

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

45/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Positive free cash flow · 86.63Weak liquidity · 0.5Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

JAGX

Analyst sentiment

Based on 5 analyst votes · 2026-09-04

100/100

Bullish

Hold

Bearish

Price Target

2026-08-23

Low

$3.21

Mean

$3.21

Median

$3.21

High

$3.21

Company Overview

IPO: 5/12/2015

Industry: Biotechnology

P/B i: 0.07

Debt / Equity i: -2.52

Operating Margin: -398.82%

Net Margin: -465.42%

ROE i: -

ROIC: -

Financial Health

Score9 / 20

Debt / Equity: -2.52

Current Ratio: 0.50

Quick Ratio: 0.29

Status: Moderate

Warnings

Weak Liquidity
Weak quick ratio

Insider Transactions

Recent executive and insider activity

MICEK JOHN

Transaction: 12/11/2025

BUY

Change

+7,377

Price

$1.44

Filing

03/12/2026

Type

BUY

MICEK JOHN

Transaction: 12/11/2025

BUY

Change

+7,377

Price

Not reported

Filing

03/12/2026

Type

BUY

Wolin Jonathan S.

Transaction: 12/11/2025

BUY

Change

+11,740

Price

$1.44

Filing

01/21/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
MICEK JOHN	BUY	+7,377	$1.44	12/11/2025	03/12/2026
MICEK JOHN	BUY	+7,377	Not reported	12/11/2025	03/12/2026
Wolin Jonathan S.	BUY	+11,740	$1.44	12/11/2025	01/21/2026
Wolin Jonathan S.	BUY	+11,740	Not reported	12/11/2025	01/21/2026
CONTE LISA A	BUY	+28,592	$1.44	12/11/2025	01/21/2026
CONTE LISA A	BUY	+28,592	Not reported	12/11/2025	01/21/2026
King Steven R.	BUY	+11,740	$1.44	12/11/2025	01/21/2026
King Steven R.	BUY	+11,740	Not reported	12/11/2025	01/21/2026
Lizak Carol R.	BUY	+11,740	$1.44	12/11/2025	12/15/2025
Lizak Carol R.	BUY	+11,740	Not reported	12/11/2025	12/15/2025
Jayasuriya Anula	BUY	+5,870	$1.44	12/11/2025	12/15/2025
Jayasuriya Anula	BUY	+5,870	Not reported	12/11/2025	12/15/2025
Siegel Jonathan B.	BUY	+7,377	$1.44	12/11/2025	12/15/2025
Siegel Jonathan B.	BUY	+7,377	Not reported	12/11/2025	12/15/2025
BOCHNOWSKI JAMES J	BUY	+6,363	$1.44	12/11/2025	12/15/2025
BOCHNOWSKI JAMES J	BUY	+6,363	Not reported	12/11/2025	12/15/2025
Chaturvedi Pravin R	BUY	+11,740	$1.44	12/11/2025	12/15/2025
Chaturvedi Pravin R	BUY	+11,740	Not reported	12/11/2025	12/15/2025
Lincoln Alternative Strategies LLC	OTHER	0	Not reported	08/28/2025	08/29/2025
CONTE LISA A	BUY	+18,262	$2.70	06/24/2025	06/26/2025

About the Company

Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Source - link

Peers

BDRX CANF CLDI CNSP GNPX GRI INM KZIA SILO SXTP

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) in an infant patient due to congenital sodium diarrhea (CSD), which is caused by a mutation in the GUCY2C gene. Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric rare IF diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with IF (SBS-IF).

Accesswire

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs.

Accesswire

Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript

Seeking Alpha

Jaguar Health Reports Second Quarter 2026 Financials

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027 REMINDER: Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates (click here to register) SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2026 financial results.

Accesswire

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.

Accesswire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-20	-149.1	-13.6	135.5
2026-03-30	-71.4	-13.6	57.8
2025-11-14	-5.08	-6.28	-1.2
2025-08-14	-7.13	-10.26	-3.13
2025-05-15	-10.82	-16.7	-5.88
2025-03-31	-18.5	-14.72	3.78
2024-11-13	-59.25	-26.25	33
2024-08-13	-0.30105	-1.01	-0.70895
2024-05-14	-0.45	-0.9	-0.45
2024-04-01	-14.7	-21	-6.3
2023-11-13	-18.45	-5.7229	12.7271
2023-08-14	-22.95	-6.3253	16.6247